September 29, 2023- Dana-Farber Cancer Institute (Dana-Farber) and Beth Israel Deaconess Medical Center (BIDMC) announced plans for a comprehensive new collaboration designed to advance the future of cancer care and build the region’s only independent, free-standing inpatient hospital for adult cancer patients.
The collaboration is designed to transform the future patient experience by improving access, by better integrating innovations at the bedside, and by offering high value care. Building on both Dana-Farber’s and BIDMC’s legacies of excellence in providing compassionate, world-class patient care and innovative research, the collaboration focuses exclusively on cancer care.
While each organization will remain fully independent — including executive leadership, boards of trustees and philanthropy — the Dana-Farber Beth Israel Deaconess Cancer Collaboration leverages the expertise of both institutions.
The proposed state-of-the-art inpatient cancer hospital will operate under the license of Dana-Farber and provide adult medical oncology care. Together, Dana-Farber and BIDMC, with its affiliated physician group, Harvard Medical Faculty Physicians (HMFP), will establish a coordinated clinical and organizational structure for oncology care in the Longwood Medical Area of Boston.
At a time when our population is aging, cancer incidence is rising in younger adults and severity of illness is increasing, a forward-looking model maximizes the patient benefits of advanced technologies and treatment methods by accelerating the impact of discovery and innovation.